Effect of Rho-kinase Inhibitor, Y27632, on Porcine Corneal Endothelial Cell Culture, Inflammation and Immune Regulation

References

• Joyce NC, Meklir B, Joyce SJ, et al. Cell cycle protein expression and proliferative status in human corneal cells. Invest Ophthalmol Vis Sci. 1996;37:645–655
   PubMed Web of Science ®Google Scholar
• Lee SE, Mehra R, Fujita M, et al. Characterization of porcine corneal endothelium for xenotransplantation. Semin Ophthalmol. 2014;29:127–135
   PubMed Web of Science ®Google Scholar
• Tan DT, Dart JK, Holland EJ, et al. Corneal transplantation. Lancet. 2012;379:1749–1761
   PubMed Web of Science ®Google Scholar
• Shimazaki J. The evolution of lamellar keratoplasty. Curr Opin Ophthalmol. 2000;11:217–223
   PubMedGoogle Scholar
• Joyce NC. Proliferative capacity of the corneal endothelium. Prog Retin Eye Res. 2003;22:359–389
   PubMed Web of Science ®Google Scholar
• Engelmann K, Bednarz J, Valtink M. Prospects for endothelial transplantation. Exp Eye Res. 2004;78:573–578
   PubMed Web of Science ®Google Scholar
• Sumide T, Nishida K, Yamato M, et al. Functional human corneal endothelial cell sheets harvested from temperature-responsive culture surfaces. Faseb J. 2006;20:392–394
   PubMed Web of Science ®Google Scholar
• Koizumi N, Sakamoto Y, Okumura N, et al. Cultivated corneal endothelial cell sheet transplantation in a primate model. Invest Ophthalmol Vis Sci. 2007;48:4519–4526
   PubMed Web of Science ®Google Scholar
• Peh GS, Beuerman RW, Colman A, et al. Human corneal endothelial cell expansion for corneal endothelium transplantation: an overview. Transplantation. 2011;91:811–819
   PubMed Web of Science ®Google Scholar
• Zhu C, Joyce NC. Proliferative response of corneal endothelial cells from young and older donors. Invest Ophthalmol Vis Sci. 2004;45:1743–1751
   PubMed Web of Science ®Google Scholar
• Fujita M, Mehra R, Lee SE, et al. Comparison of proliferative capacity of genetically-engineered pig and human corneal endothelial cells. Ophthalmic Res. 2013;49:127–138
   PubMed Web of Science ®Google Scholar
• Hara H, Cooper DK. Xenotransplantation-the future of corneal transplantation? Cornea. 2011;30:371–378
   PubMed Web of Science ®Google Scholar
• Hara H, Cooper DK. The immunology of corneal xenotransplantation: a review of the literature. Xenotransplantation. 2010;17:338–349
   PubMed Web of Science ®Google Scholar
• Kim MK, Wee WR, Park CG, et al. Xenocorneal transplantation. Curr Opin Organ Transplant. 2011;16:231–236
   PubMed Web of Science ®Google Scholar
• Ekser B, Ezzelarab M, Hara H, et al. Clinical xenotransplantation: the next medical revolution? Lancet. 2012;379:672–683
   PubMed Web of Science ®Google Scholar
• Pan Z, Sun C, Jie Y, et al. WZS-pig is a potential donor alternative in corneal xenotransplantation. Xenotransplantation. 2007;14:603–611
   PubMed Web of Science ®Google Scholar
• Choi HJ, Kim MK, Lee HJ, et al. Efficacy of pig-to-rhesus lamellar corneal xenotransplantation. Invest Ophthalmol Vis Sci. 2011;52:6643–6650
   PubMed Web of Science ®Google Scholar
• Li A, Pan Z, Jie Y, et al. Comparison of immunogenicity and porcine-to-rhesus lamellar corneal xenografts survival between fresh preserved and dehydrated porcine corneas. Xenotransplantation. 2011;18:46–55
   PubMed Web of Science ®Google Scholar
• Hara H, Koike N, Long C, et al. Initial in vitro investigation of the human immune response to corneal cells from genetically engineered pigs. Invest Ophthalmol Vis Sci. 2011;52:5278–5286
   PubMed Web of Science ®Google Scholar
• Nicholls SM, Mitchard LK, Laycock GM, et al. A model of corneal graft rejection in semi-inbred NIH miniature swine: significant T-cell infiltration of clinically accepted allografts. Invest Ophthalmol Vis Sci. 2012;53:3183–3192
   PubMedGoogle Scholar
• Okumura N, Koizumi N, Ueno M, et al. ROCK inhibitor converts corneal endothelial cells into a phenotype capable of regenerating in vivo endothelial tissue. Am J Pathol. 2012;181:268–277
   PubMed Web of Science ®Google Scholar
• Okumura N, Ueno M, Koizumi N, et al. Enhancement on primate corneal endothelial cell survival in vitro by a ROCK inhibitor. Invest Ophthalmol Vis Sci. 2009;50:3680–3687
   PubMed Web of Science ®Google Scholar
• Pipparelli A, Arsenijevic Y, Thuret G, et al. ROCK inhibitor enhances adhesion and wound healing of human corneal endothelial cells. PLoS One. 2013;8:e62095
   PubMed Web of Science ®Google Scholar
• Claassen DA, Desler MM, Rizzino A. ROCK inhibition enhances the recovery and growth of cryopreserved human embryonic stem cells and human induced pluripotent stem cells. Mol Reprod Dev. 2009;76:722–732
   PubMed Web of Science ®Google Scholar
• Koizumi N, Okumura N, Kinoshita S. Development of new therapeutic modalities for corneal endothelial disease focused on the proliferation of corneal endothelial cells using animal models. Exp Eye Res. 2012;95:60–67
   PubMed Web of Science ®Google Scholar
• Okumura N, Koizumi N, Kay EP, et al. The ROCK inhibitor eye drop accelerates corneal endothelium wound healing. Invest Ophthalmol Vis Sci. 2013;54:2493–2502
   PubMed Web of Science ®Google Scholar
• Inoue T, Tanihara H. Rho-associated kinase inhibitors: a novel glaucoma therapy. Prog Retin Eye Res. 2013;37:1–12
   PubMed Web of Science ®Google Scholar
• Challa P, Arnold JJ. Rho-kinase inhibitors offer a new approach in the treatment of glaucoma. Expert Opin Investig Drugs. 2014;23:81–95
   PubMed Web of Science ®Google Scholar
• Hippenstiel S, Soeth S, Kellas B, et al. Rho proteins and the p38-MAPK pathway are important mediators for LPS-induced interleukin-8 expression in human endothelial cells. Blood. 2000;95:3044–3051
   PubMed Web of Science ®Google Scholar
• Segain JP, Raingeard de la Bletiere D, Sauzeau V, et al. Rho kinase blockade prevents inflammation via nuclear factor kappa B inhibition: evidence in Crohn’s disease and experimental colitis. Gastroenterology. 2003;124:1180–1187
   PubMed Web of Science ®Google Scholar
• He Y, Xu H, Liang L, et al. Antiinflammatory effect of Rho kinase blockade via inhibition of NF-kappaB activation in rheumatoid arthritis. Arthritis Rheum. 2008;58:3366–3376
   PubMed Web of Science ®Google Scholar
• Wojciak-Stothard B, Williams L, Ridley AJ. Monocyte adhesion and spreading on human endothelial cells is dependent on Rho-regulated receptor clustering. J Cell Biol. 1999;145:1293–1307
   PubMed Web of Science ®Google Scholar
• Takemoto M, Sun J, Hiroki J, et al. Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase. Circulation. 2002;106:57–62
   PubMed Web of Science ®Google Scholar
• Chen LY, Zuraw BL, Liu FT, et al. IL-1 receptor-associated kinase and low molecular weight GTPase RhoA signal molecules are required for bacterial lipopolysaccharide-induced cytokine gene transcription. J Immunol. 2002;169:3934–3939
   PubMed Web of Science ®Google Scholar
• Hiroki J, Shimokawa H, Higashi M, et al. Inflammatory stimuli upregulate Rho-kinase in human coronary vascular smooth muscle cells. J Mol Cell Cardiol. 2004;37:537–546
   PubMed Web of Science ®Google Scholar
• Anwar KN, Fazal F, Malik AB, et al. RhoA/Rho-associated kinase pathway selectively regulates thrombin-induced intercellular adhesion molecule-1 expression in endothelial cells via activation of I kappa B kinase beta and phosphorylation of RelA/p65. J Immunol. 2004;173:6965–6972
   PubMed Web of Science ®Google Scholar
• Matoba K, Kawanami D, Ishizawa S, et al. Rho-kinase mediates TNF-alpha-induced MCP-1 expression via p38 MAPK signaling pathway in mesangial cells. Biochem Biophys Res Commun. 2010;402:725–730
   PubMed Web of Science ®Google Scholar
• Kawanami D, Matoba K, Kanazawa Y, et al. Thrombin induces MCP-1 expression through Rho-kinase and subsequent p38MAPK/NF-kappaB signaling pathway activation in vascular endothelial cells. Biochem Biophys Res Commun. 2011;411:798–803
   PubMed Web of Science ®Google Scholar
• Li H, Peng W, Jian W, et al. ROCK inhibitor fasudil attenuated high glucose-induced MCP-1 and VCAM-1 expression and monocyte-endothelial cell adhesion. Cardiovasc Diabetol. 2012;11:65
   PubMed Web of Science ®Google Scholar
• Hara H, Witt W, Crossley T, et al. Human dominant-negative class II transactivator transgenic pigs - effect on the human anti-pig T-cell immune response and immune status. Immunology. 2013;140:39–46
   PubMed Web of Science ®Google Scholar
• Long C, Hara H, Pawlikowski Z, et al. Genetically engineered pig red blood cells for clinical transfusion: initial in vitro studies. Transfusion. 2009;49:2418–2429
   PubMed Web of Science ®Google Scholar
• Firaguay G, Nunes JA. Analysis of signaling events by dynamic phosphoflow cytometry. Sci Signal. 2009;2:pl3
   PubMed Web of Science ®Google Scholar
• Iwase H, Ekser B, Satyananda V, et al. Initial in vivo experience of pig artery patch transplantation in baboons using mutant MHC (CIITA-DN) pigs. Transpl Immunol. 2015;32:99–108
   PubMed Web of Science ®Google Scholar
• Yamagami H, Yamagami S, Inoki T, et al. The effects of proinflammatory cytokines on cytokine-chemokine gene expression profiles in the human corneal endothelium. Invest Ophthalmol Vis Sci. 2003;44:514–520
   PubMed Web of Science ®Google Scholar
• Torres PF, Slegers TP, Peek R, et al. Changes in cytokine mRNA levels in experimental corneal allografts after local clodronate-liposome treatment. Invest Ophthalmol Vis Sci. 1999;40:3194–3201
   PubMed Web of Science ®Google Scholar
• Bachmann BO, Bock F, Wiegand SJ, et al. Promotion of graft survival by vascular endothelial growth factor a neutralization after high-risk corneal transplantation. Arch Ophthalmol. 2008;126:71–77
   PubMed Web of Science ®Google Scholar
• Niederkorn JY. Immune mechanisms of corneal allograft rejection. Curr Eye Res. 2007;32:1005–1016
   PubMed Web of Science ®Google Scholar
• Joyce NC. Proliferative capacity of corneal endothelial cells. Exp Eye Res. 2012;95:16–23
   PubMed Web of Science ®Google Scholar
• Olson MF, Ashworth A, Hall A. An essential role for Rho, Rac, and Cdc42 GTPases in cell cycle progression through G1. Science. 1995;269:1270–1272
   PubMed Web of Science ®Google Scholar
• Riento K, Ridley AJ. Rocks: multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol. 2003;4:446–456
   PubMed Web of Science ®Google Scholar
• Coleman ML, Marshall CJ, Olson MF. RAS and RHO GTPases in G1-phase cell-cycle regulation. Nat Rev Mol Cell Biol. 2004;5:355–366
   PubMed Web of Science ®Google Scholar
• Okumura N, Koizumi N, Ueno M, et al. Enhancement of corneal endothelium wound healing by Rho-associated kinase (ROCK) inhibitor eye drops. Br J Ophthalmol. 2011;95:1006–1009
   PubMed Web of Science ®Google Scholar
• Okumura N, Koizumi N, Ueno M, et al. The new therapeutic concept of using a rho kinase inhibitor for the treatment of corneal endothelial dysfunction. Cornea. 2011;30:1S54–1S59
   Google Scholar
• Okumura N, Nakano S, Kay EP, et al. Involvement of cyclin D and p27 in cell proliferation mediated by ROCK inhibitors Y-27632 and Y-39983 during corneal endothelium wound healing. Invest Ophthalmol Vis Sci. 2014;55:318–329
   PubMed Web of Science ®Google Scholar
• Joyce NC, Zhu CC. Human corneal endothelial cell proliferation: potential for use in regenerative medicine. Cornea. 2004;23:S8–S19
   PubMedGoogle Scholar
• Enomoto K, Mimura T, Harris DL, et al. Age differences in cyclin-dependent kinase inhibitor expression and rb hyperphosphorylation in human corneal endothelial cells. Invest Ophthalmol Vis Sci. 2006;47:4330–4340
   PubMed Web of Science ®Google Scholar
• Ing JJ, Ing HH, Nelson LR, et al. Ten-year postoperative results of penetrating keratoplasty. Ophthalmology. 1998;105:1855–1865
   PubMed Web of Science ®Google Scholar
• Tharaux PL, Bukoski RC, Rocha PN, et al. Rho kinase promotes alloimmune responses by regulating the proliferation and structure of T cells. J Immunol. 2003;171:96–105
   PubMed Web of Science ®Google Scholar
• Liao JK, Seto M, Noma K. Rho kinase (ROCK) inhibitors. J Cardiovasc Pharmacol. 2007;50:17–24
   PubMed Web of Science ®Google Scholar
• Yin L, Morishige K, Takahashi T, et al. Fasudil inhibits vascular endothelial growth factor-induced angiogenesis in vitro and in vivo. Mol Cancer Ther. 2007;6:1517–1525
   PubMed Web of Science ®Google Scholar
• Olson MF. Applications for ROCK kinase inhibition. Curr Opin Cell Biol. 2008;20:242–248
   PubMed Web of Science ®Google Scholar
• Okamoto H, Yoshio T, Kaneko H, et al. Inhibition of NF-kappaB signaling by fasudil as a potential therapeutic strategy for rheumatoid arthritis. Arthritis Rheum. 2010;62:82–92
   PubMed Web of Science ®Google Scholar
• Funding M, Hansen TK, Gjedsted J, et al. Simultaneous quantification of 17 immune mediators in aqueous humour from patients with corneal rejection. Acta Ophthalmol Scand. 2006;84:759–765
   PubMedGoogle Scholar
• Spandau UH, Toksoy A, Verhaart S, et al. High expression of chemokines Gro-alpha (CXCL-1), IL-8(CXCL-8), and MCP-1(CCL-2) in inflamed human corneas in vivo. Arch Ophthalmol. 2003;121:825–831
   PubMed Web of Science ®Google Scholar
• Kvanta A, Sarman S, Fagerholm P, et al. Expression of matrix metalloproteinase-2(MMP-2) and vascular endothelial growth factor (VEGF) in inflammation-associated corneal neovascularization. Exp Eye Res. 2000;70:419–428
   PubMed Web of Science ®Google Scholar
• Kaur J, Woodman RC, Kubes P. P38 MAPK: critical molecule in thrombin-induced NF-kappa B-dependent leukocyte recruitment. Am J Physiol Heart Circ Physiol. 2003;284:H1095–H1103
   PubMed Web of Science ®Google Scholar
• Costello PS, Walters AE, Mee PJ, et al. The Rho-family GTP exchange factor Vav is a critical transducer of T cell receptor signals to the calcium, ERK, and NF-kappaB pathways. Proc Natl Acad Sci U S A. 1999;96:3035–3040
   PubMed Web of Science ®Google Scholar
• Lee JR, Ha YJ, Kim HJ. Cutting edge: induced expression of a RhoA-specific guanine nucleotide exchange factor, p190RhoGEF, following CD40 stimulation and WEHI 231 B cell activation. J Immunol. 2003;170:19–23
   PubMed Web of Science ®Google Scholar
• Salazar-Fontana LI, Barr V, Samelson LE, et al. CD28 engagement promotes actin polymerization through the activation of the small Rho GTPase Cdc42 in human T cells. J Immunol. 2003;171:2225–2232
   PubMed Web of Science ®Google Scholar
• Hattori T, Shimokawa H, Higashi M, et al. Long-term treatment with a specific Rho-kinase inhibitor suppresses cardiac allograft vasculopathy in mice. Circ Res. 2004;94:46–52
   PubMed Web of Science ®Google Scholar
• Liu M, Gu M, Wu Y, et al. Therapeutic effect of Y-27632 on chronic allograft nephropathy in rats. J Surg Res. 2009;157:e117–e127
   PubMed Web of Science ®Google Scholar
• Poosti F, Yazdani S, Dolman ME, et al. Targeted inhibition of renal Rho kinase reduces macrophage infiltration and lymphangiogenesis in acute renal allograft rejection. Eur J Pharmacol. 2012;694:111–119
   PubMed Web of Science ®Google Scholar
• Ohki S, Iizuka K, Ishikawa S, et al. A highly selective inhibitor of Rho-associated coiled-coil forming protein kinase, Y-27632, prolongs cardiac allograft survival of the BALB/c-to-C3H/He mouse model. J Heart Lung Transplant. 2001;20:956–963
   PubMed Web of Science ®Google Scholar
• Yin J, Yu FS. Rho kinases regulate corneal epithelial wound healing. Am J Physiol Cell Physiol. 2008;295:C378–C387
   PubMed Web of Science ®Google Scholar
• Tokushige H, Inatani M, Nemoto S, et al. Effects of topical administration of y-39983, a selective rho-associated protein kinase inhibitor, on ocular tissues in rabbits and monkeys. Invest Ophthalmol Vis Sci. 2007;48:3216–3222
   PubMed Web of Science ®Google Scholar